WallStSmart

America Movil SAB de CV ADR (AMX)vsEdwards Lifesciences Corp (EW)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

America Movil SAB de CV ADR generates 15452% more annual revenue ($943.64B vs $6.07B). EW leads profitability with a 17.7% profit margin vs 8.8%. AMX appears more attractively valued with a PEG of 1.17. AMX earns a higher WallStSmart Score of 69/100 (B-).

AMX

Strong Buy

69

out of 100

Grade: B-

Growth: 4.0Profit: 7.0Value: 10.0Quality: 4.0
Piotroski: 6/9Altman Z: 1.37

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMXUndervalued (+67.3%)

Margin of Safety

+67.3%

Fair Value

$72.07

Current Price

$24.76

$47.31 discount

UndervaluedFair: $72.07Overvalued
EWSignificantly Overvalued (-544.4%)

Margin of Safety

-544.4%

Fair Value

$12.31

Current Price

$82.67

$70.36 premium

UndervaluedFair: $12.31Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMX5 strengths · Avg: 8.8/10
Free Cash FlowQuality
$42.68B10/10

Generating 42.7B in free cash flow

Market CapQuality
$70.61B9/10

Large-cap with strong market position

Return on EquityProfitability
20.5%9/10

Every $100 of equity generates 21 in profit

P/E RatioValuation
15.2x8/10

Attractively priced relative to earnings

Operating MarginProfitability
20.1%8/10

Strong operational efficiency at 20.1%

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

Areas to Watch

AMX4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.4%4/10

3.4% revenue growth

EPS GrowthGrowth
4.0%4/10

4.0% earnings growth

Price/BookValuation
72.8x2/10

Trading at 72.8x book value

Altman Z-ScoreHealth
1.372/10

Distress zone — elevated risk

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.7x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : AMX

The strongest argument for AMX centers on Free Cash Flow, Market Cap, Return on Equity. PEG of 1.17 suggests the stock is reasonably priced for its growth.

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bear Case : AMX

The primary concerns for AMX are Revenue Growth, EPS Growth, Price/Book. Debt-to-equity of 2.53 is elevated, increasing financial risk.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.

Key Dynamics to Monitor

AMX profiles as a value stock while EW is a mature play — different risk/reward profiles.

EW carries more volatility with a beta of 0.93 — expect wider price swings.

EW is growing revenue faster at 13.3% — sustainability is the question.

AMX generates stronger free cash flow (42.7B), providing more financial flexibility.

Bottom Line

AMX scores higher overall (69/100 vs 55/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

America Movil SAB de CV ADR

COMMUNICATION SERVICES · TELECOM SERVICES · USA

Amrica Mvil, SAB de CV provides telecommunications services in Latin America and internationally. The company is headquartered in Mexico City, Mexico.

Visit Website →

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Want to dig deeper into these stocks?